Related Experiment Video
Updated: Dec 18, 2025

Monitoring Stub1-Mediated Pexophagy
Published on: May 12, 2023
Myotubularin-related protein 7 activates peroxisome proliferator-activated receptor-gamma
Philip Weidner1, Michaela Söhn1, Torsten Schroeder1
1Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Abstract:
Peroxisome proliferator-activated receptor-gamma (PPARγ) is a transcription factor drugable by agonists approved for treatment of type 2 diabetes, but also inhibits carcinogenesis and cell proliferation in vivo. Activating mutations in the Kirsten rat sarcoma viral oncogene homologue (KRAS) gene mitigate these beneficial effects by promoting a negative feedback-loop comprising extracellular signal-regulated kinase 1/2 (ERK1/2) and mitogen-activated kinase kinase 1/2 (MEK1/2)-dependent inactivation of PPARγ. To overcome this inhibitory mechanism, we searched for novel post-translational regulators of PPARγ. Phosphoinositide phosphatase Myotubularin-Related-Protein-7 (MTMR7) was identified as cytosolic interaction partner of PPARγ. Synthetic peptides were designed resembling the regulatory coiled-coil (CC) domain of MTMR7, and their activities studied in human cancer cell lines and C57BL6/J mice. MTMR7 formed a complex with PPARγ and increased its transcriptional activity by inhibiting ERK1/2-dependent phosphorylation of PPARγ. MTMR7-CC peptides mimicked PPARγ-activation in vitro and in vivo due to LXXLL motifs in the CC domain. Molecular dynamics simulations and docking predicted that peptides interact with the steroid receptor coactivator 1 (SRC1)-binding site of PPARγ. Thus, MTMR7 is a positive regulator of PPARγ, and its mimicry by synthetic peptides overcomes inhibitory mechanisms active in cancer cells possibly contributing to the failure of clinical studies targeting PPARγ.
Insights
Myotubularin-Related-Protein-7 (MTMR7) activates Peroxisome proliferator-activated receptor-gamma (PPARγ), a key factor in diabetes and cancer. Synthetic peptides mimicking MTMR7 overcome cancer-related inhibition, offering new therapeutic potential.
Area of Science:
- Molecular Biology
- Oncology
- Endocrinology
Background:
- Peroxisome proliferator-activated receptor-gamma (PPARγ) agonists treat type 2 diabetes but are hindered in cancer treatment by KRAS mutations.
- Activating KRAS mutations induce a feedback loop (ERK1/2/MEK1/2) that inactivates PPARγ, limiting its anti-cancer effects.
Purpose of the Study:
- To identify novel post-translational regulators of PPARγ.
- To develop strategies to overcome KRAS-mediated inhibition of PPARγ for potential cancer therapy.
Main Methods:
- Identified Myotubularin-Related-Protein-7 (MTMR7) as a PPARγ interaction partner.
- Designed and tested synthetic MTMR7 coiled-coil (CC) domain peptides.
- Utilized molecular dynamics simulations and docking to predict peptide-PPARγ interactions.
Main Results:
- MTMR7 forms a complex with PPARγ, enhancing its transcriptional activity by inhibiting ERK1/2-dependent phosphorylation.
- MTMR7-CC peptides mimic PPARγ activation in vitro and in vivo, independent of KRAS-driven inhibition.
- Peptides bind to the PPARγ SRC1-binding site, suggesting a mechanism for enhanced activity.
Conclusions:
- MTMR7 is a positive regulator of PPARγ.
- Synthetic MTMR7-CC peptides can overcome inhibitory mechanisms in cancer cells.
- This approach may address limitations observed in clinical studies targeting PPARγ for cancer treatment.
More Related Videos
Related Concept Videos
Protein Import into the Peroxisomes
Peroxisomal Protein Import:
Peroxisomes lack the genetic machinery required to code for their own proteins. Hence, most peroxisomal membrane, lumenal and transmembrane proteins are synthesized in the cytoplasm or ER and transported to the peroxisome...
PI3K/mTOR/AKT Signaling Pathway
Master Transcription Regulators
The Unfolded Protein Response
TGF - β Signaling Pathway
Peroxisomes

